230 related articles for article (PubMed ID: 30912670)
1. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
[TBL] [Abstract][Full Text] [Related]
4. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
5. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
7. A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo.
Zárate AM; Espinosa-Bustos C; Guerrero S; Fierro A; Oyarzún-Ampuero F; Quest AFG; Di Marcotullio L; Loricchio E; Caimano M; Calcaterra A; González-Quiroz M; Aguirre A; Meléndez J; Salas CO
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445078
[TBL] [Abstract][Full Text] [Related]
8. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
9. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation.
Wang Y; Arvanites AC; Davidow L; Blanchard J; Lam K; Yoo JW; Coy S; Rubin LL; McMahon AP
ACS Chem Biol; 2012 Jun; 7(6):1040-8. PubMed ID: 22554036
[TBL] [Abstract][Full Text] [Related]
10. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
11. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
[TBL] [Abstract][Full Text] [Related]
13. Overcoming the resistance mechanisms of Smoothened inhibitors.
Dong X; Wang C; Chen Z; Zhao W
Drug Discov Today; 2018 Mar; 23(3):704-710. PubMed ID: 29326074
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Hedgehog Antagonists for Cancer Therapy.
Khatra H; Bose C; Sinha S
Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010
[TBL] [Abstract][Full Text] [Related]
15. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.
Kaboli PJ; Bazrafkan M; Ismail P; Ling KH
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581
[TBL] [Abstract][Full Text] [Related]
16. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies.
Galperin I; Dempwolff L; Diederich WE; Lauth M
J Med Chem; 2019 Sep; 62(18):8392-8411. PubMed ID: 30986059
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.
Chahal KK; Li J; Kufareva I; Parle M; Durden DL; Wechsler-Reya RJ; Chen CC; Abagyan R
PLoS One; 2019; 14(9):e0214901. PubMed ID: 31539380
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
20. Current trends in Hedgehog signaling pathway inhibition by small molecules.
Ghirga F; Mori M; Infante P
Bioorg Med Chem Lett; 2018 Oct; 28(19):3131-3140. PubMed ID: 30177379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
